Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer

CD44v6, the CD44 isoform mostly involved in cancer cell migration and invasion, has been identified as a functional biomarker and therapeutic target in colon cancer stem cells. We here provide evidence that baseline CD44v6-positive CTC predict treatment failure in patients with metastatic colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolazzo, Chiara, Loreni, Flavia, Caponnetto, Salvatore, Magri, Valentina, Vestri, Anna Rita, Zamarchi, Rita, Gradilone, Angela, Facchinetti, Antonella, Rossi, Elisabetta, Cortesi, Enrico, Gazzaniga, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665234/
https://www.ncbi.nlm.nih.gov/pubmed/33227095
http://dx.doi.org/10.18632/oncotarget.27794
Descripción
Sumario:CD44v6, the CD44 isoform mostly involved in cancer cell migration and invasion, has been identified as a functional biomarker and therapeutic target in colon cancer stem cells. We here provide evidence that baseline CD44v6-positive CTC predict treatment failure in patients with metastatic colorectal cancer undergoing first-line chemotherapy. We suggest that CD44v6-positive CTC can be used to early detect intrinsic drug resistance in this cancer type.

Ejemplares similares